American Century Companies Inc. Has $9.69 Million Stock Holdings in Solventum Co. (NYSE:SOLV)

American Century Companies Inc. boosted its position in shares of Solventum Co. (NYSE:SOLV - Free Report) by 43.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 146,608 shares of the company's stock after acquiring an additional 44,251 shares during the period. American Century Companies Inc. owned 0.08% of Solventum worth $9,685,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the company. State Street Corp grew its position in Solventum by 3.1% in the 3rd quarter. State Street Corp now owns 6,107,550 shares of the company's stock worth $425,818,000 after purchasing an additional 185,938 shares during the last quarter. Geode Capital Management LLC grew its position in Solventum by 4.0% during the third quarter. Geode Capital Management LLC now owns 3,347,719 shares of the company's stock worth $232,608,000 after buying an additional 128,317 shares in the last quarter. Boston Partners bought a new position in Solventum during the fourth quarter valued at about $110,378,000. Bank of New York Mellon Corp raised its holdings in Solventum by 4.1% in the 4th quarter. Bank of New York Mellon Corp now owns 943,699 shares of the company's stock valued at $62,341,000 after acquiring an additional 36,907 shares in the last quarter. Finally, Point72 Asset Management L.P. bought a new stake in shares of Solventum in the 3rd quarter worth approximately $50,948,000.

Solventum Price Performance

Shares of SOLV stock traded down $0.95 during trading hours on Monday, hitting $65.25. 2,859,227 shares of the company's stock were exchanged, compared to its average volume of 1,365,494. Solventum Co. has a 52 week low of $47.16 and a 52 week high of $85.92. The stock has a market cap of $11.29 billion and a price-to-earnings ratio of 23.73. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83. The stock's 50-day moving average is $75.23 and its 200-day moving average is $71.90.

Analyst Ratings Changes

A number of analysts have recently issued reports on the company. Bank of America boosted their price objective on Solventum from $80.00 to $85.00 and gave the company a "neutral" rating in a research report on Wednesday, February 26th. Mizuho increased their price objective on shares of Solventum from $70.00 to $82.00 and gave the company a "neutral" rating in a research note on Monday, March 3rd. Piper Sandler lifted their target price on shares of Solventum from $75.00 to $84.00 and gave the company a "neutral" rating in a research report on Friday, February 28th. Wells Fargo & Company increased their price target on shares of Solventum from $73.00 to $75.00 and gave the stock an "equal weight" rating in a research report on Friday, February 28th. Finally, Morgan Stanley lifted their price objective on Solventum from $73.00 to $80.00 and gave the company an "equal weight" rating in a report on Wednesday, March 5th. One analyst has rated the stock with a sell rating, eight have given a hold rating and one has assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $79.86.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.